Sun Pharmaceutical share analysis
Sun Pharmaceutical passes 6 of 6 fundamental tests, a score of 10/10. On the daily chart it is in a sideways range, RSI 37, 14% below its 52-week high: range-bound: no edge either way. Its own volatility puts the likely range at ₹1,664–₹1,859 a month from now and ₹1,451–₹2,133 in a year (68% bands).
Fundamentals 10/10
- Market cap
- ₹4,21,995 Cr
- P/E · forward
- 34.9 · 27.1
- PEG · P/B
- 1.0 · 5.0
- ROE · net margin
- — · +20%
- Revenue · earnings growth
- +11% · +27%
- Debt / equity
- 6%
- Dividend · beta
- 0.9% · 0.1
- Next results
- 30 Oct 2026
- ✓ Net margin above 10%
- ✓ Revenue growing over 10%
- ✓ Earnings growing
- ✓ Debt/equity under 100%
- ✓ Forward P/E under trailing (earnings expected up)
- ✓ PEG under 2
Swing technicals (daily)
- Trend
- sideways · 50d above 200d
- RSI(14)
- 37
- 20 / 50 / 200-day avg
- ₹1,806 / ₹1,866 / ₹1,808
- 20-day breakout
- above ₹1,892 · below ₹1,726
- ATR(14)
- ₹32.54 (1.9% a day)
- 52-week range
- ₹1,584 – ₹2,047
- Return 3m · 6m · 1y
- -9% · +4% · +5%
What the price could do
| In | Likely range (68%) |
|---|---|
| 1 mo | ₹1,664 – ₹1,859 (-5% / +6%) |
| 3 mo | ₹1,597 – ₹1,937 (-9% / +10%) |
| 6 mo | ₹1,535 – ₹2,016 (-13% / +15%) |
| 1 year | ₹1,451 – ₹2,133 (-18% / +21%) |
Analysts (32): buy, mean target ₹2,174 (+24%)
From its own volatility (19% a year), no drift assumed: what its swings allow, not a forecast.
Sun Pharmaceutical news · last two days
News lean: Neutral- 3d agoSun Pharmaceutical Industries Share PriceBusiness Standard
- 4d agoSun Pharma down 2%, stock hits over 5-month lowBusiness Standard
- 4d agoSun Pharma to Raise Rs 10,000 Cr via NCDs; Director ResignsRediff Money
- 4d agoGeojit raises target for Sun Pharma stock to INR 2,070.00Ad Hoc News
- 5d agoStocks to Watch Today (Oct 13): HCLTech, RBL Bank, Nazara Technologies, Sun Pharma and moreZee Business
Its order flow and footprint, the AI read of every headline, the expected move, and your own holdings beside it, with your broker connected.
Information and analytics for education only, not investment advice or a recommendation to buy or sell. Alephix Intelligence is not registered with SEBI as an investment adviser or research analyst. Prices may be delayed; figures come from public market data.